BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12105157)

  • 1. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
    Altman R; Luciardi HL; Muntaner J; Del Rio F; Berman SG; Lopez R; Gonzalez C
    Circulation; 2002 Jul; 106(2):191-5. PubMed ID: 12105157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 inhibition and cardiovascular events.
    Pitt B; Pepine C; Willerson JT
    Circulation; 2002 Jul; 106(2):167-9. PubMed ID: 12105151
    [No Abstract]   [Full Text] [Related]  

  • 3. Meloxicam: selective COX-2 inhibition in clinical practice.
    Furst DE
    Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
    JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
    Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
    Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
    Goodman SG; Fitchett D; Armstrong PW; Tan M; Langer A;
    Circulation; 2003 Jan; 107(2):238-44. PubMed ID: 12538422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
    Cohen M; Stinnett SS; Weatherley BD; Gurfinkel EP; Fromell GJ; Goodman SG; Fox KA; Califf RM
    Am Heart J; 2000 Jun; 139(6):962-70. PubMed ID: 10827375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
    Anand SS
    Am J Cardiol; 1999 Sep; 84(5A):13M-19M. PubMed ID: 10505538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
    Miyamoto K; Oka N; Kawasaki T; Miyake S; Yamamura T; Akiguchi I
    Muscle Nerve; 2002 Feb; 25(2):280-2. PubMed ID: 11870698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meloxicam in acute UV dermatitis--a pilot study.
    Bayerl C; Pagung R; Jung EG
    Photodermatol Photoimmunol Photomed; 1998; 14(5-6):167-9. PubMed ID: 9826888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
    Gibson CM; Pride YB; Aylward PE; Col JJ; Goodman SG; Gulba D; Bergovec M; Kunadian V; Zorkun C; Buros JL; Murphy SA; Antman EM
    J Thromb Thrombolysis; 2009 Jan; 27(1):11-7. PubMed ID: 18695943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat.
    Gupta YK; Chaudhary G; Sinha K
    Can J Physiol Pharmacol; 2002 Mar; 80(3):210-7. PubMed ID: 11991232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
    Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
    Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.